Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study
Authors' conclusion
BMs from non-ATC are associated with poor survival and marked prognostic heterogeneity.
Study context
- Population
- Adults with histologically confirmed non-ATC (nonanaplastic follicular cell-derived thyroid carcinoma) and radiologically documented brain metastases; median age at BM diagnosis 59 years (IQR 48–67)
- Participants
- 189 adults
- Outcome
- PFS and OS
Methodological detailsinternational, multicenter, 19 tertiary referral centers
- International
- Multicenter
- 19 tertiary referral centers
Main finding
As reported in the abstract
Median PFS (IQR: 2.9-22.4)
7.0 months
Median overall survival (OS) (IQR: 4.0-38.4)
15.0 months
non-ATC GPA: four prognostic groups, median OS in highest-score group
72.6 months
non-ATC GPA: median OS in lowest-score group
3.7 months
Observational data: associations, not effects.
Further findings
First-line BM treatments
- Stereotactic radiosurgery
- 27.0%
- Neurosurgery
- 23.8%
- Whole-brain radiotherapy
- 18.5%
- Best supportive care
- 10.6%
Exploratory SEER-based assessment of adapted GPA prognostic groups
- Survival differences across adapted prognostic groups
- P = 0.036
- Limited by the absence of all key GPA variables
Original publication
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study. Thyroid. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →